ReviewLeukemia2008
Epigenetic plasticity of chromatin in embryonic and hematopoietic stem/progenitor cells: therapeutic potential of cell reprogramming.
Review in Leukemia, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 62 citations in OpenAlex.
- The paradox of nuclear miRNAs: Mechanisms, therapeutic potential, and future directions.Non-coding RNA research · 2026Review
- How ATP-Dependent Chromatin Remodeling Complexes Regulate Vertebrate Embryonic Development.International journal of molecular sciences · 2026Review
- Nuclear miRNAs: Gene Regulation Activities.International journal of molecular sciences · 2024Review
- Noncanonical functions of microRNAs in the nucleus.Acta biochimica et biophysica Sinica · 2024Review
- Vitamin A - discovery, metabolism, receptor signaling and effects on bone mass and fracture susceptibility.Frontiers in endocrinology · 2024Review
- The Histone Deacetylase Inhibitor I1 Induces Differentiation of Acute Leukemia Cells With MLL Gene RearrangementsFrontiers in pharmacology · 2022Article
- The Histone Deacetylase Inhibitor I13 Induces Differentiation of M2, M3 and M5 Subtypes of Acute Myeloid Leukemia Cells and Leukemic Stem-Like Cells.Frontiers in oncology · 2022Article
- The Role of H3K4 Trimethylation in CpG Islands Hypermethylation in Cancer.Biomolecules · 2021Review
- Hematopoietic Differentiation of Human Pluripotent Stem Cells: HOX and GATA Transcription Factors as Master Regulators.Current genomics · 2019Review
- Prediction of Gene Expression Patterns With Generalized Linear Regression Model.Frontiers in genetics · 2019Article
- Engineering Lineage Potency and Plasticity of Stem Cells using Epigenetic Molecules.Scientific reports · 2018Article
- A small-molecule/cytokine combination enhances hematopoietic stem cell proliferation via inhibition of cell differentiation.Stem cell research & therapy · 2017Article
- Maintenance of leukemic cell identity by the activity of the Polycomb complex PRC1 in mice.Science advances · 2016Article
- Maintenance of the functional integrity of mouse hematopoiesis by EED and promotion of leukemogenesis by EED haploinsufficiency.Scientific reports · 2016Article
- Epigenetic treatment of solid tumours: a review of clinical trials.Clinical epigenetics · 2015Review
- Identification of epigenetic modifications that contribute to pathogenesis in therapy-related AML: Effective integration of genome-wide histone modification with transcriptional profiles.BMC medical genomics · 2015Article
- The epigenetic regulator CXXC finger protein 1 is essential for murine hematopoiesis.PloS one · 2014Article
- DNA looping facilitates targeting of a chromatin remodeling enzyme.Molecular cell · 2013Article
- The epigenome of AML stem and progenitor cells.Epigenetics · 2013Article
- The reactive stroma microenvironment and prostate cancer progression.Endocrine-related cancer · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During embryonic development and adult life, the plasticity and reversibility of modifications that affect the chromatin structure is important in the expression of genes involved in cell fate decisions and the maintenance of cell-differentiated state. Epigenetic changes in DNA and chromatin, which must occur to allow the accessibility of transcriptional factors at specific DNA-binding sites, are regarded as emerging major players for embryonic and hematopoietic stem cell (HSC) development and lineage differentiation. Epigenetic deregulation of gene expression, whether it be in conjunction with chromosomal alterations and gene mutations or not, is a newly recognized mechanism that leads to several diseases, including leukemia. The reversibility of epigenetic modifications makes DNA and chromatin changes attractive targets for therapeutic intervention. Here we review some of the epigenetic mechanisms that regulate gene expression in pluripotent embryonic and multipotent HSCs but may be deregulated in leukemia, and the clinical approaches designed to target the chromatin structure in leukemic cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.